RCEL Valuation

AVITA Medical Inc

Add to Watchlist

Advanced Chart

8.620

-0.010(-0.120%)

Overview
Forecast
Valuation

RCEL Relative Valuation

RCEL's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, RCEL is overvalued; if below, it's undervalued.

Historical Valuation

AVITA Medical Inc (RCEL) is now in the Fair zone, suggesting that its current forward PS ratio of 2.26 is considered Fairly compared with the five-year average of 9.19. The fair price of AVITA Medical Inc (RCEL) is between 7.12 to 52.06 according to relative valuation methord.

Relative Value

Fair Zone

7.12-52.06

Current Price：8.62

Fair

P/E

EV/EBITDA

EV/EBIT

P/S

P/OCF

P/FCF

Trailing

Forward

50.49

P/B

Median3y

9.78

Median5y

8.03

-25.47

FCF Yield

Median3y

-14.27

Median5y

-10.77

Competitors Valuation Multiple

The average P/S ratio for RCEL's competitors is 1.76, providing a benchmark for relative valuation. AVITA Medical Inc Corp (RCEL) exhibits a P/S ratio of 2.26, which is 28.66% above the industry average. Given its robust revenue growth of 29.67%, this premium appears sustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

Revenue Growth

Market Cap